4.6 Review

C3 glomerulonephritis and CFHR5 nephropathy

Journal

NEPHROLOGY DIALYSIS TRANSPLANTATION
Volume 28, Issue 2, Pages 282-288

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/ndt/gfs441

Keywords

complement; C3; CFHR5; glomerulonephritis; genetics

Funding

  1. MRC
  2. Medical Research Council [G1002528] Funding Source: researchfish
  3. National Institute for Health Research [NF-SI-0507-10315] Funding Source: researchfish
  4. Wellcome Trust [096956/Z/11/Z] Funding Source: researchfish
  5. Wellcome Trust [096956/Z/11/Z] Funding Source: Wellcome Trust
  6. MRC [G1002528] Funding Source: UKRI

Ask authors/readers for more resources

Complement is an important aspect of defence against infection and its activation and regulation are finely balanced. Disordered complement regulation can lead to C3 glomerulonephritis (C3GN), which is characterized by complement (but not immunoglobulin) deposition in the glomerulus of the kidney. Although only recently recognized as a clinical entity, C3GN is important and elucidation of its molecular causes, by studies of single cases and families, has identified key proteins that protect the kidney from complement-mediated damage. The commonest cause of C3GN is complement factor H-related 5 (CFHR5) nephropathy, which is endemic in Greek Cypriots. Genetic evidence implicates some of the same complement regulators in the aetiology of common immune complex glomerular disorders such as IgA nephropathy and lupus nephritis. Importantly, therapeutic manipulation of the complement pathway is now feasible. An exciting challenge is to determine whether this can be applied to kidney diseases that are caused by complement dysregulation, and also whether they might be used to intervene in other kidney diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available